Form 4: Replimune Group Director Weinand Acquires 32,000 Stock Options

Director Dieter Weinand of Replimune Group, Inc. reports acquiring 32,000 stock options on April 1, 2024, exercisable at $7.73, according to a Form 4 filing.

Summary

• Dieter Weinand, a director of Replimune Group, Inc., filed a Form 4 disclosing a transaction on April 1, 2024.
• Weinand acquired 32,000 stock options with an exercise price of $7.73.
• These options vest entirely on April 1, 2025, and expire on April 1, 2034.
• Following the reported transaction, Weinand directly owns 32,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider transactions can sometimes signal confidence, this is a standard part of executive compensation.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's activity in acquiring stock options, which is a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates